{"id":4305,"date":"2026-11-12T17:00:00","date_gmt":"2026-11-12T21:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4305"},"modified":"2026-11-14T12:48:22","modified_gmt":"2026-11-14T16:48:22","slug":"baloncibart-phase-2-signal-in-pots","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4305","title":{"rendered":"Baloncibart Phase 2 Signal in POTS"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Regeneron_Therapeutic_Indications-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4312\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Regeneron_Therapeutic_Indications-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Regeneron_Therapeutic_Indications-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Regeneron_Therapeutic_Indications-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Regeneron_Therapeutic_Indications-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Regeneron_Therapeutic_Indications.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Regeneron<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Randomized Phase 2 results (PINNACLE)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Monoclonal antibody<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Baloncibart (REGN7544)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>NPR1<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Postural orthostatic tachycardia syndrome<\/p>\n<h4>Summary<\/h4>\n<p>Regeneron disclosed randomized Phase 2 PINNACLE results for NPR1-blocking baloncibart in postural orthostatic tachycardia syndrome. The 450 mg dose lowered the day-eight standing heart-rate increment versus placebo by a least-squares mean 11.4 beats per minute, with nominal evidence of persistence to day 29.<\/p>\n<p>The primary company disclosure was posted November 12 at 5:00 p.m. EST and first presented at the American Autonomic Society meeting. Eighty-two adults received a single subcutaneous 150 mg dose, 450 mg dose or placebo (27, 28 and 27 participants). No formal hypothesis testing was prespecified, so p values are nominal. At day 29, the 450 mg difference in orthostatic heart-rate change was \u22127.4 bpm; the 150 mg effect was not maintained. Patient-reported orthostatic symptoms and physical function improved nominally at 450 mg, while activities-of-daily-living difference did not reach conventional significance. Treatment-emergent adverse events occurred in 67.9% at 450 mg versus 48.1% with placebo; one serious syncope event occurred at 450 mg.<\/p>\n<h4>Deep Analysis<\/h4>\n<p>NPR1 blockade is intended to expand effective circulating volume. Increased NT-proBNP and lower standing norepinephrine and hemoglobin are consistent with that mechanism, but are not direct proof of durable volume restoration. <strong>Interpretation A:<\/strong> convergent physiologic and symptom measures support a causal treatment effect and a pivotal trial.<\/p>\n<p><strong>Interpretation B:<\/strong> small cohorts, no prespecified multiplicity-controlled hypothesis test and a novel patient-reported instrument could inflate apparent certainty. Blood-pressure change and syncope merit careful safety follow-up. The single-dose four-week window cannot establish chronic treatment benefit or long-term tolerability.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>POTS is an autonomic syndrome involving excessive heart-rate rise on standing and disabling symptoms. Baloncibart (REGN7544) is an investigational monoclonal antibody against natriuretic peptide receptor 1, intended to modulate fluid balance and orthostatic physiology.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Signal: first mid-stage human efficacy evidence for a new POTS antibody mechanism.<\/li>\n<li>Missing: full protocol and statistical plan, longer follow-up, reproducible symptom effects, dose optimization and subgroup response.<\/li>\n<li>Upgrade: a controlled Phase 3 with prespecified clinical endpoints and safety monitoring.<\/li>\n<li>Downgrade or falsify: failure to reproduce symptom\/function benefit despite heart-rate change, or a clinically material volume or blood-pressure safety liability.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>Baloncibart merits pivotal testing, but the result should be described as a Phase 2 signal rather than confirmed efficacy. Regulatory acceptance and commercial readiness remain unproven.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: positive. Confidence in Facts: high for disclosed randomized results. Confidence in Interpretation: moderate because the trial is small and p values nominal.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Regeneron disclosed randomized Phase 2 PINNACLE results for NPR1-blocking baloncibart in postural orthostatic tachycardia syndrome. The 450 mg dose lowered the day-eight standing heart-rate increment versus placebo by a least-squares mean 11.4 beats per&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4312,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1489,1490,121],"class_list":["post-4305","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-baloncibart","tag-pots","tag-regeneron"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4305"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4305\/revisions"}],"predecessor-version":[{"id":4330,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4305\/revisions\/4330"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4312"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}